2024-518273-34-02招募中1 期
Safety, Tolerability and Efficacy against Controlled Human Malaria Infection of PfSPZ-LARC2 Vaccine in Malaria-naïve Adults
Universitaetsklinikum Tuebingen AöR1 个研究点 分布在 1 个国家目标入组 42 人开始时间: 2026年1月26日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 发起方
- 入组人数
- 42
- 试验地点
- 1
研究概览
简要总结
暂无简介。
入排标准
- 年龄范围
- 18 years 至 64 years（18-64 Years）
- 接受健康志愿者
- 是
入选标准
- 未提供
排除标准
- 未提供
研究者
Prof. Dr. Peter Kremsner
Scientific
Universitaetsklinikum Tuebingen AöR
研究点 (1)
Loading locations...
相似试验
招募中
1 期
A Study Evaluating the Safety and Tolerability of a Novel Formulation of QRL-101 in Healthy Participants2025-524310-28-00Quralis Corp.48
已完成
1 期
A Study to Evaluate the Safety and Tolerability of JNJ-77730614 When Given as Single and Multiple Doses to Healthy Participants to Assess How Long JNJ 77730614 Stays in the Body (Pharmacokinetics) and How the Body Responds to it (Pharmacodynamics)2023-505684-36-00Janssen - Cilag International92
招募中
1 期
A study to evaluate the safety and tolerability of single ascending doses of AGMB-101 in healthy participants (Part A) and patients with liver cirrhosis (Part B).2024-515074-26-00AgomAb Therapeutics64
已完成
1 期
A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of Zosurabalpin following Intravenous Administration in Healthy Participants2023-505411-20-00F. Hoffmann-La Roche AG, F. Hoffmann-La Roche AG30
招募中
1 期
A study investigating the safety, tolerability, metabolism, and elimination of INE963, a new compound in the treatment of malaria.Malaria2024-516911-26-00Novartis Pharma AG94